Lindbrook Capital’s Lifecore Biomedical LFCR Stock Holding History

Lindbrook Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-65	Closed	-$1K	–	2635
2022 Q1	$1K	Buy	+65	New	+$724	﹤0.01%	2280

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's LFCR Position: Q2 2022 in Review

Lindbrook Capital sold out of Lifecore Biomedical (LFCR) in Q2 2022, closing a stake of 65 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in LFCR in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 90 funds tracked by Wall St. Rank hold LFCR as of Q2 2022.

Lindbrook Capital reported no remaining Lifecore Biomedical position as of Q2 2022 after selling out during the quarter.
Lindbrook Capital sold 65 Lifecore Biomedical shares in Q2 2022, an estimated $1K.
Lindbrook Capital first reported a position in Lifecore Biomedical in Q1 2022 and held it in 1 quarter.
Lindbrook Capital's Lifecore Biomedical position peaked at $1K in Q1 2022.
90 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2022.

Based on Lindbrook Capital's 13F filing for Q2 2022, filed 1 Aug 2022.